Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 348

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 3
Chunk 348
---
 under certain intellectual property
rights controlled by AstraZeneca related to HK-4 Glucokinase activators AZD1656 and AZD5658 in all indications and myeloperoxidase inhibitor
AZD5904 for the treatment, prevention, and prophylaxis of idiopathic male infertility. The Company will be responsible for the development
and commercialization of the Licensed Products under the related License Agreement. The
Company is required to use commercially reasonable efforts to develop and commercialize the Licensed Products.

AstraZeneca
has conducted initial pre-clinical and, in some instances, clinical trials on these assets, but has decided to license them for further
development. As the clinical assets have undergone initial pre-clinical and clinical testing conducted by AstraZeneca, we are able to
use the safety data generated in these clinical trials to assess which clinical assets to further develop and for which indications.

Through
this relationship, there are considerable APIs that were manufactured by AstraZeneca
(prior to conducting its clinical trials) available to Conduit. As a result, Conduit may not have to develop the APIs, which is often
a time consuming and expensive process, and the APIs already produced were subject to rigorous quality control measures.

In
collaboration with SARBORG Limited (“Sarborg”), a related party, Conduit intends to leverage an advanced AI and cybernetics platform to evaluate key deliverables across multiple areas of the Company’s operations,
including drug repurposing, drug discovery, solid-form identification, and clinical trial monitoring.

The
Sarborg Agreement is designed to address longstanding challenges in the pharmaceutical sector, in particular by reducing human error
in critical decision-making processes in both clinical development and asset identification. By integrating Sarborg’s
algorithmic AI/cybernetics technology, Conduit aims to enhance efficiency, lower costs, and accelerate timelines by minimizing human
intervention, ultimately optimizing the drug development cycle and giving Conduit a competitive advantage in the sector.

Through
this relationship, Conduit will gain access to cutting-edge predictive models and dashboards, enabling the Company to evaluate drug candidates,
streamline clinical trials, and optimize asset management with real-time data. These tools will drive faster, more accurate decisions,
improving efficiency and reducing costs. By leveraging these insights, Conduit can differentiate itself in a competitive sector and gain
unique data-driven insights that position the Company for success across both its current and future asset portfolio.

In
addition, Con